Lumos Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Lumos Pharma (LUMO) to Neutral from Buy with a price target of $4.25, down from $28, after the company entered into a definitive merger agreement whereby Double Point Ventures will acquire 100% of Lumos’ outstanding shares of common stock at a price of $4.25 per share in cash.